NEWARK, Del., September 29, 2026 — According to Future Market Insights, the global Kidney Transplant AlloSure dd-cfDNA Monitoring Market is valued at USD 592.6 million in 2026 and is projected to reach USD 1,315.4 million by 2036, expanding at a CAGR of 8.3% during the 2026–2036 forecast period. Demand is supported by transplant programs seeking repeatable molecular evidence for graft surveillance between routine follow-up visits and invasive diagnostic procedures. CareDx reported in August 2025 that its KOAR study enrolled 1,743 recipients across 56 United States transplant centers and collected 18,584 AlloSure tests, supporting the use of serial testing within structured surveillance pathways.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-34172
Global Segment Leaders
- Test Type – Donor-derived Cell-free DNA Monitoring: 35.7% share in 2026 — Leads because it directly measures graft-derived molecular material across serial blood samples and can identify unexpected graft-injury signals.
- Application – Acute Rejection Monitoring: 30.6% share in 2026 — Leads as transplant teams require timely molecular evidence when changing graft function triggers diagnostic escalation or treatment review.
- End User – Transplant Centers: 37.1% share in 2026 — Transplant centers control surveillance protocols and coordinate laboratory ordering, nephrology review, pathology input, and biopsy decisions.
- Transplant Type – Deceased Donor Kidney Transplantation: 33.0% share in 2026 — Leads because of its substantial procedure base and the complex early follow-up associated with varied ischemic exposure.
Country-Level Performance
- USA – 10.1% CAGR: UNOS reported 27,573 kidney transplants during 2025, including 21,052 deceased-donor and 6,521 living-donor procedures, supporting demand across extensive transplant-center and laboratory networks.
- UK – 9.8% CAGR: NHS Blood and Transplant reported in 2026 that the kidney waiting list reached 8,237 people, supporting demand for stronger graft assessment within national transplant services.
- Japan – 9.6% CAGR: The Japan Organ Transplant Network reported 14,983 registered kidney candidates on June 30, 2026, supporting continued interest in noninvasive post-transplant monitoring.
- South Korea – 9.3% CAGR: The Korea National Institute of Health reported in July 2025 that 83 centers participated in its nationwide transplant cohort, with the cohort targeting more than 2,000 new registrations annually.
- Germany – 7.6% CAGR: The Federal Institute for Public Health reported in January 2026 that 1,495 kidneys were recovered from deceased donors during 2025, while 8,199 people remained on organ waiting lists.
The USA records the highest CAGR among the five profiled countries at 10.1%, followed by the UK at 9.8%, Japan at 9.6%, South Korea at 9.3%, and Germany at 7.6%.
Regional Context
Fast-growing markets: The USA, UK, Japan, and South Korea form the higher-growth group, with CAGRs ranging from 9.3% to 10.1%. The USA benefits from large transplant-center networks, centralized laboratory access, and established reimbursement routes. The UK is supported by centralized service governance and national clinical networks. Japan’s specialized transplant centers and large registered candidate population support noninvasive monitoring, while South Korea combines tertiary-care infrastructure with multicenter research capability.
Slower-growth market: Germany records the lowest CAGR among the five profiled markets at 7.6%. FMI attributes the more measured trajectory to decentralized laboratory purchasing, IVDR-compliant local assay requirements, specialist laboratory capacity, and decentralized reimbursement and validation costs.
The full report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa, with country-level coverage extending across the United States, Canada, Brazil, Mexico, Argentina, Chile, Germany, France, the UK, Italy, Spain, China, Japan, South Korea, India, Australia, and additional national markets.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-34172
Market Drivers, Restraints and Opportunities
Protocol-based surveillance is the principal growth driver. Transplant programs require repeatable molecular evidence that can support risk stratification during routine follow-up and help determine when additional diagnostic evaluation is warranted. CareDx’s KOAR studies provide multicenter evidence supporting serial monitoring, including a June 2026 analysis involving 1,258 adult recipients across 56 U.S. centers.
Reimbursement and testing protocols remain restraints. Coverage policies can limit testing frequency even when clinicians see value in serial measurements. In July 2026, the Centers for Medicare & Medicaid Services published final response documents for its MolDX solid-organ rejection testing policy following stakeholder comments, establishing defined testing-frequency and clinical-use requirements for covered molecular services.
Integrated reporting represents an opportunity. Combining dd-cfDNA results with donor-specific antibodies and routine clinical variables can give transplant teams a more complete view of each surveillance episode. CareDx announced AlloSure Plus in July 2025, combining dd-cfDNA with established clinical methods for rejection prediction.
Competitive Landscape
The competitive landscape includes CareDx, Natera, Eurofins Viracor, Insight Molecular Diagnostics, Thermo Fisher Scientific, Devyser Diagnostics, Bio-Rad Laboratories, and Omixon. CareDx and Natera provide centralized kidney dd-cfDNA services with clinical interpretation and multicenter evidence, while Eurofins Viracor and Insight Molecular Diagnostics provide additional clinical testing routes. Thermo Fisher Scientific and Devyser Diagnostics support local laboratory deployment through NGS kits and interpretation software, while Bio-Rad Laboratories and Omixon provide platform or workflow capabilities for decentralized testing.
Key Developments
- March 2025: CareDx expanded AlloSure Kidney availability to patients receiving simultaneous pancreas-kidney transplants following validation and commercial availability through review by the New York State Clinical Laboratory Evaluation Program.
- November 2025: Devyser Diagnostics enrolled the first participant in a U.S. clinical study of its Accept cfDNA assay, with the prospective observational program planned to enroll up to 400 kidney recipients across six transplant centers.
- June 2026: Natera and Eledon Pharmaceuticals announced that Prospera would serve as the exclusive dd-cfDNA monitoring assay in Eledon’s planned Phase 3 kidney-transplant trial targeting approximately 600 recipients across more than 100 centers.
- January 2025: Insight Molecular Diagnostics announced expanded Medicare coverage for VitaGraft Kidney among recipients with newly developed donor-specific antibodies, covering monitoring for antibody-mediated rejection.
Access Full Report: https://www.futuremarketinsights.com/reports/kidney-transplant-allosure-dd-cfdna-monitoring-market
Analyst Perspective
“The strongest evidence base in dd-cfDNA monitoring comes from studies tracking trends over time rather than single measurements, which is why longitudinal programs like Natera’s PEDAL study following nearly 500 recipients across dozens of centers carry more clinical weight than a snapshot result. Deceased donor recipients complicate this picture further, since delayed graft function from ischemic exposure can mimic or mask a genuine injury signal during early recovery, making baseline sampling protocols as important as the assay itself. Transplant centers that tie ordering directly into nephrology and pathology workflows will likely see more consistent adoption than programs treating the test as an add-on, since turnaround time only matters if a clinic’s follow-up schedule is built to act on the result.”
— Anurag Sharma, Principal Consultant, Future Market Insights
About Future Market Insights
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and biotechnology.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
